Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

XenoPort, Inc. (XNPT - Snapshot Report) recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study (n=228).

Results from the phase III trial showed that AP failed to achieve statistically significant improvement compared to placebo in patients suffering from spasticity due to multiple sclerosis (MS).

AP’s failure in the phase III study is a major disappointment and setback for the company.

The company was looking to submit a new drug application (NDA) for AP in the US at the end of 2013.

However, XenoPort has now decided to terminate any further studies on this program.

Shares were down 15.2% on the news.

We believe that the successful development and commercialization of AP would have boosted XenoPort’s portfolio which currently comprises only one approved drug, Horizant.

Going forward, XenoPort will shift its focus to its fumarate product candidate XP2389 along with investing in the commercialization of its prime drug, Horizant.

We note that XenoPort obtained the development and commercialization rights on Horizant in the US from GlaxoSmithKline plc (GSK - Analyst Report), effective May 1, 2013, following the termination of their collaboration agreement in Nov 2012.

Horizant is approved in the US for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as for the management of postherpetic neuralgia (PHN) in adults.

However, Horizant faces stiff competition for both indications. Pfizer’s (PFE - Analyst Report) Neurontin competes with Horizant for the PHN indication.

XenoPort currently carries a Zacks Rank #3 (Hold). Right now, Anika Therapeutics, Inc. looks attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%